Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer

• Verfasst von: Reck, Martin [VerfasserIn]
• Verfasst von: von Pawel, J. [VerfasserIn]
• Verfasst von: Zatloukal, P. [VerfasserIn]
• Verfasst von: Ramlau, R. [VerfasserIn]
• Verfasst von: Gorbounova, V. [VerfasserIn]
• Verfasst von: Hirsh, V. [VerfasserIn]
• Verfasst von: Leighl, N. [VerfasserIn]
• Verfasst von: Mezger, J. [VerfasserIn]
• Verfasst von: Archer, V. [VerfasserIn]
• Verfasst von: Moore, N. [VerfasserIn]
• Verfasst von: Manegold, Christian [VerfasserIn]
• Titel: Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer
• Titelzusatz: results from a randomised phase III trial (AVAiL)
• Verf.angabe: M. Reck, J. von Pawel, P. Zatloukal, R. Ramlau, V. Gorbounova, V. Hirsh, N. Leighl, J. Mezger, V. Archer, N. Moore, C. Manegold & BO17704 Study Group
• E-Jahr: 2010
• Jahr: September 2010
• Umfang: 6 S.
• Fussnoten: Elektronische Reproduktion der Druckausgabe ; Gesehen am 11.05.2023
• Titel Quelle: Enthalten in: Annals of oncology
• Ort Quelle: Amsterdam [u.a.] : Elsevier, 1990
• Jahr Quelle: 2010
• Band/Heft Quelle: 21(2010), 9 vom: Sept., Seite 1804-1809
• ISSN Quelle: 1569-8041
• DOI: doi:10.1093/annonc/mdq020
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: bevacizumab
• Sach-SW: chemotherapy
• Sach-SW: NSCLC
• Sach-SW: overall survival
• Sach-SW: vascular endothelial growth factor
• K10plus-PPN: 184517898X

Abstract

Background - Bevacizumab, the anti-vascular endothelial growth factor agent, provides clinical benefit when combined with platinum-based chemotherapy in first-line advanced non-small-cell lung cancer. We report the final overall survival (OS) analysis from the phase III AVAiL trial. - Patients and methods - Patients (n=1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n=345), bevacizumab 15 mg/kg (n=351) or placebo (n=347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. - Results - Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64-0.87), P=0.0003 and 0.85 (0.73-1.00), P=0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78-1.11), P=0.420 and 1.03 (0.86-1.23), P=0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (∼62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. - Conclusions - Final analysis of AVAiL confirms the efficacy of bevacizumab when combined with cisplatin-gemcitabine. The PFS benefit did not translate into a significant OS benefit, possibly due to high use of efficacious second-line therapies.